Glaucoma News

SAN FRANCISCO — More new cases of glaucoma were diagnosed in pseudoexfoliation eyes compared with control eyes after phacoemulsification, according to 5-year results of the Aravind Pseudoexfoliation Study presented here.

SAN FRANCISCO — Upon FDA approval of the fixed-dose glaucoma treatment Rocklatan, Aerie Pharmaceuticals’ next step is launching the product.

A cohort of patients with open-angle glaucoma or ocular hypertension implanted with an iStent after cataract surgery experienced reduced, safe and durable IOP and reduced medications through 5 years after the procedure, according to a study.

NEW ORLEANS – Artificial intelligence and telemedicine are already embedded in today’s eye care practice, but the human component will never be replaced, according to panelists discussing imaging and diagnostics at the Ophthalmic Innovation Summit, held here during SECO.

The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop, for patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

NEW ORLEANS – It is time to change the glaucoma treatment paradigm, Ike K. Ahmed, MD, said here at SECO.

NEW ORLEANS – A multitude of treatments options in development for the ocular surface, retina and glaucoma have the potential to greatly improve patient outcomes and quality of life, Chris Wroten, OD, DiplABO, said here at SECO.

NEW ORLEANS – A panel here at the Ophthalmic Innovation Summit, held during SECO, recognized the dramatic advances made in the field of glaucoma technology and therapeutics but also recognized the challenges with implementation.

Visual crowding significantly affects patients with glaucoma and may have a high impact on daily tasks such as driving, reading and identifying objects, according to a study.

Patients with glaucoma, even at the early stage, read slowly and with more errors as compared with normal subjects, according to a study.